BioNTech Braces for Multi-Front Patent War as Vaccine Revenues Fade and Oncology Costs Mount
Published on 07/19/2026 at 13:11 | Redaktion boerse-global.de
The transition from pandemic-era juggernaut to oncology-focused biotech was never going to be easy, but BioNTech is now navigating that pivot while facing a rapidly thickening thicket of patent litigation. The company reported first-quarter 2026 revenue of just €118.1 million, down sharply from the peak of €17.3 billion in 2022, and posted a net loss of €531.9 million. Management’s full-year guidance of €2.0 billion to €2.3 billion underscores how far the COVID vaccine franchise has shrunk, even as the company pours between €2.2 billion and €2.5 billion into research and development this year to build its oncology pipeline.
That expensive reinvention is being complicated by a new wave of legal challenges. In mid-July 2026, Arbutus Biopharma and Genevant Sciences filed additional patent lawsuits in Canada and Europe, targeting the lipid nanoparticle technology used in the Comirnaty vaccine developed with Pfizer. The move expands a running dispute that already spans the United States. Arbutus was emboldened by a recent $178 million settlement with Moderna over similar claims, and is now seeking damages and permanent injunctions against BioNTech and its partner. Adding to the pressure, French pharmaceutical giant Sanofi has also filed its own patent claim concerning Comirnaty, widening the circle of adversaries.
At the heart of the litigation is the lipid nanoparticle delivery system that makes mRNA vaccines viable. The technology, supplied for BioNTech’s shot by Vancouver-based Acuitas Therapeutics, is essential: without it, the vaccine cannot function, according to Acuitas chief Thomas Madden. The same formulation also explains why the vaccine originally required storage at minus 70 degrees Celsius — long-term stability data at higher temperatures were simply unavailable during the early rollout. Whoever ultimately controls the patents on these nanoparticles will wield significant leverage over mRNA-based medicine.
Should investors sell immediately? Or is it worth buying BioNTech?
The legal uncertainty has not yet crushed the stock, but it adds another layer of risk to an already contentious valuation picture. BioNTech currently trades at a price-to-sales ratio of 7.2, below the biotech sector average of 11.3 but slightly above its direct peer group’s 6.4. Analyst targets are all over the map, ranging from $94 at TD Cowen to $158 at Canaccord Genuity. Morgan Stanley trimmed its target to $119 on July 8, while UBS upgraded to Buy in late May with a $135 target. The wide dispersion reflects the difficulty of weighing the fading vaccine business against a pipeline that has yet to deliver a commercial product.
The share price itself has remained range-bound. BioNTech closed at €80.20 on Friday, roughly 1.23% above its 50-day moving average of €79.23, suggesting a market that is marking time rather than betting directionally. That leaves the stock 24% below its 52-week high of €105.80, set on January 22, and nursing a 16.28% decline over the past twelve months. With a market capitalisation just shy of €20 billion, the company is still a heavyweight, but the combination of evaporating vaccine profits, eye-watering R&D spending, and an expanding patent docket creates plenty of overhead.
Investors will get their next checkpoint on August 4, when BioNTech reports second-quarter results. That update is likely to include more detail on how the legal costs and potential liability from the lawsuits are feeding into the company’s expense base, as well as progress on the oncology pipeline that is supposed to carry the business into the 2030s. For now, the stock remains caught between a patent storm and a high-stakes turnaround.
Ad
BioNTech Stock: New Analysis - 19 July
Fresh BioNTech information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
